Literature DB >> 14650906

Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus.

Laura A Volpicelli1, Allan I Levey.   

Abstract

The M1, M2 and M4 subtypes of mAChRs are the predominant receptors in the CNS. These receptors activate a multitude of signaling pathways important for modulating neuronal excitability, synaptic plasticity and feedback regulation of ACh release. In addition, novel functions mediated by mAChRs are currently being discovered. These studies are greatly facilitated by the recent development of subtype selective toxins and mice lacking individual mAChR genes. Studies in cell culture and the rodent brain demonstrate that mAChR internalization and intracellular trafficking is an important component of mAChR regulation. Characterizing mAChR intracellular trafficking could help facilitate the development of selective mAChR ligands. For example, a selective M1 agonist would cause a shift in the distribution of M1 from the cell surface to an intracellular distribution, while M2 and M4 would remain on the cell surface. Characterizing mAChR intracellular trafficking is also important for understanding the cellular mechanisms that regulate mAChR cell surface expression and signaling. Furthermore, intracellular trafficking has recently been demonstrated to play a role in the development of tolerance to drugs (Whistler et al., 1999; He et al., 2002). Because individual mAChR subtypes are novel targets for treatments of diseases such as Alzheimer's disease and schizophrenia, understanding the mechanisms that regulate mAChR signaling and intracellular trafficking following acute and chronic stimulation might lead to the development of rational strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14650906     DOI: 10.1016/S0079-6123(03)45003-6

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  79 in total

1.  Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.

Authors:  Evan P Lebois; Gregory J Digby; Douglas J Sheffler; Bruce J Melancon; James C Tarr; Hyekyung P Cho; Nicole R Miller; Ryan Morrison; Thomas M Bridges; Zixiu Xiang; J Scott Daniels; Michael R Wood; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2011-08-24       Impact factor: 2.823

2.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Authors:  Evan P Lebois; Thomas M Bridges; L Michelle Lewis; Eric S Dawson; Alexander S Kane; Zixiu Xiang; Satyawan B Jadhav; Huiyong Yin; J Phillip Kennedy; Jens Meiler; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; C David Weaver; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2010       Impact factor: 4.418

3.  M-type potassium channels modulate Schaffer collateral-CA1 glutamatergic synaptic transmission.

Authors:  Jianli Sun; Jaideep Kapur
Journal:  J Physiol       Date:  2012-06-06       Impact factor: 5.182

Review 4.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

5.  Neuronal localization of m1 muscarinic receptor immunoreactivity in the rat basolateral amygdala.

Authors:  Alexander Joseph McDonald; Franco Mascagni
Journal:  Brain Struct Funct       Date:  2010-05-26       Impact factor: 3.270

Review 6.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

7.  Preliminary evidence for associations of CHRM2 with substance use and disinhibition in adolescence.

Authors:  Christian S Hendershot; Angela D Bryan; Sarah W Feldstein Ewing; Eric D Claus; Kent E Hutchison
Journal:  J Abnorm Child Psychol       Date:  2011-07

8.  Anticholinergics and central nervous system effects: are we confused?

Authors:  David R Staskin; Edward Zoltan
Journal:  Rev Urol       Date:  2007

9.  Recovery of network-driven glutamatergic activity in rat hippocampal neurons during chronic glutamate receptor blockade.

Authors:  Eric Leininger; Andrei B Belousov
Journal:  Brain Res       Date:  2008-11-25       Impact factor: 3.252

Review 10.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.